Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating e-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 2, 2013, Pages 206-214

  Mateen, Samiha ^a   Raina, Komal ^a   Agarwal, Chapla ^a,b   Chan, Daniel ^b,c   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE INHIBITOR; SILIBININ; TRANSCRIPTION FACTOR ZEB1; TRICHOSTATIN A; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG POTENTIATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HUMAN; HUMAN CELL; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION; UPREGULATION;

ANTIOXIDANTS; AZACITIDINE; BLOTTING, WESTERN; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; DRUG SYNERGISM; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE SILENCING; HISTONE DEACETYLASE INHIBITORS; HOMEODOMAIN PROTEINS; HUMANS; HYDROXAMIC ACIDS; NEOPLASM INVASIVENESS; SILYMARIN; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84876401638     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.203471     Document Type: Article

References (60)

1. Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn CO, Heidecke CD, Friess H, Büchler M, Evert M, and Lerch MM, et al. (2012) Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61:439-448.
2. Beavon IR (2000) The E-cadherin-catenin complex in tumour metastasis: Structure, function and regulation. Eur J Cancer 36 (13 Spec No):1607-1620. (Pubitemid 30616365)
3. Belinsky SA (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4:707-717. (Pubitemid 39215069)
4. Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG, March TH, and Baylin SB (2003) Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 63:7089-7093. (Pubitemid 37413444)
5. Bots M and Johnstone RW (2009) Rational combinations using HDAC inhibitors. Clin Cancer Res 15:3970-3977.
6. Bowman RV, Yang IA, Semmler AB, and Fong KM (2006) Epigenetics of lung cancer. Respirology 11:355-365. (Pubitemid 43824331)
7. Bremnes RM, Veve R, Hirsch FR, and Franklin WA (2002) The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer 36:115-124. (Pubitemid 34302891)
8. Chaffer CL and Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331:1559-1564.
9. Chang J, Varghese DS, Gillam MC, Peyton M, Modi B, Schiltz RL, Girard L, and Martinez ED (2012) Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Br J Cancer 106:116-125.
10. Clarhaut J, Gemmill RM, Potiron VA, Ait-Si-Ali S, Imbert J, Drabkin HA, and Roche J (2009) ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells. Neoplasia 11:157-166.
11. Denlinger CE, Ikonomidis JS, Reed CE, and Spinale FG (2010) Epithelial to mesenchymal transition: The doorway to metastasis in human lung cancers. J Thorac Cardiovasc Surg 140:505-513.
12. Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, and Fishbein MC, et al. (2006) Cyclooxygenase-2-dependent regulation of E-cadherin: Prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res 66:5338-5345. (Pubitemid 43844959)
13. Drake JM, Strohbehn G, Bair TB, Moreland JG, and Henry MD (2009) ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol Biol Cell 20:2207-2217.
14. Fantin VR and Richon VM (2007) Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 13:7237-7242.
15. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, and Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
16. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA, Jr, and Raben D (2007) Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 6:1683-1691. (Pubitemid 46954044)
17. Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, and Drabkin HA (2011) ZEB1-responsive genes in nonsmall cell lung cancer. Cancer Lett 300:66-78.
18. Hanahan D and Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144:646-674.
19. Issa JP and Kantarjian HM (2009) Targeting DNA methylation. Clin Cancer Res 15: 3938-3946.
20. Johnstone RW (2002) Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299. (Pubitemid 37361445)
21. Jones PA and Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428. (Pubitemid 34587077)
22. Kakihana M, Ohira T, Chan D, Webster RB, Kato H, Drabkin HA, and Gemmill RM (2009) Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. J Thorac Oncol 4:1455-1465.
23. Le TL, Yap AS, and Stow JL (1999) Recycling of E-cadherin: A potential mechanism for regulating cadherin dynamics. J Cell Biol 146:219-232. (Pubitemid 29349976)
24. Lim SC, Jang IG, Kim YC, and Park KO (2000) The role of E-cadherin expression in non-small cell lung cancer. J Korean Med Sci 15:501-506.
25. Liu YN, Lee WW, Wang CY, Chao TH, Chen Y, and Chen JH (2005) Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene 24:8277-8290. (Pubitemid 43250920)
26. Marks PA, Richon VM, and Rifkind RA (2000) Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216. (Pubitemid 30627729)
27. Mateen S, Raina K, Jain AK, Agarwal C, Chan D, and Agarwal R (2012) Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small-cell lung cancer cells. Epigenetics 10:1161-1172.
28. Mateen S, Tyagi A, Agarwal C, Singh RP, and Agarwal R (2010) Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators. Mol Carcinog 49: 247-258.
29. Meeran SM, Ahmed A, and Tollefsbol TO (2010) Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenetics 1:101-116.
30. Nawrocki-Raby B, Gilles C, Polette M, Bruyneel E, Laronze JY, Bonnet N, Foidart JM, Mareel M, and Birembaut P (2003) Upregulation of MMPs by soluble E-cadherin in human lung tumor cells. Int J Cancer 105:790-795. (Pubitemid 36706102)
31. Neal JW and Sequist LV (2012) Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 30:2280-2282.
32. Nephew KP and Huang TH (2003) Epigenetic gene silencing in cancer initiation and progression. Cancer Lett 190:125-133. (Pubitemid 36136010)
33. Ohira T, Gemmill RM, Ferguson K, Kusy S, Roche J, Brambilla E, Zeng C, Baron A, Bemis L, and Erickson P, et al. (2003) WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci USA 100:10429-10434. (Pubitemid 37071895)
34. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, and Weinberg RA (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68:3645-3654.
35. Pece S and Gutkind JS (2002) E-cadherin and Hakai: Signalling, remodeling or destruction? Nat Cell Biol 4:E72-E74. (Pubitemid 34308843)
36. Peinado H, Portillo F, and Cano A (2004) Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48:365-375. (Pubitemid 39360388)
37. Postigo AA and Dean DC (1999) ZEB represses transcription through interaction with the corepressor CtBP. Proc Natl Acad Sci USA 96:6683-6688. (Pubitemid 29274943)
38. Ramasamy K, Dwyer-Nield LD, Serkova NJ, Hasebroock KM, Tyagi A, Raina K, Singh RP, Malkinson AM, and Agarwal R (2011) Silibinin prevents lung tumorigenesis in wild-type but not in iNOS-/-mice: Potential of real-time micro-CT in lung cancer chemoprevention studies. Clin Cancer Res 17:753-761.
39. Robey RW, Chakraborty AR, Basseville A, Luchenko V, Bahr J, Zhan Z, and Bates SE (2011) Histone deacetylase inhibitors: Emerging mechanisms of resistance. Mol Pharm 8:2021-2031.
40. Schmalhofer O, Brabletz S, and Brabletz T (2009) E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28:151-166.
41. Schrump DS (2009) Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: Mechanisms and potential clinical implications. Clin Cancer Res 15: 3947-3957.
42. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, and Pollack JR, et al. (2006) A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3:e486.
43. Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM, and Agarwal R (2006) Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst 98:846-855. (Pubitemid 43923441)
44. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, and Kristiansen G (2008) Prognostic significance of epithelial- mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res 14:7430-7437.
45. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A, Hlubek F, Jung A, Strand D, and Eger A, et al. (2008) The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 68:537-544. (Pubitemid 351380082)
46. Strathdee G (2002) Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin Cancer Biol 12:373-379.
47. Tang M, Xu W, Wang Q, Xiao W, and Xu R (2009) Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy. Curr Genomics 10:336-352.
48. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454.
49. Thompson EW, Newgreen DF, and Tarin D (2005) Carcinoma invasion and metastasis: A role for epithelial-mesenchymal transition? Cancer Res 65:5991-5995, discussion 5995. (Pubitemid 40994377)
50. Tsuji T, Ibaragi S, and Hu GF (2009) Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 69:7135-7139.
51. Tyagi A, Agarwal C, Dwyer-Nield LD, Singh RP, Malkinson AM, and Agarwal R (2011) Silibinin modulates TNF-alpha and IFN-gamma mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells. Mol Carcinog 51:832-842.
52. Tyagi A, Singh RP, Ramasamy K, Raina K, Redente EF, Dwyer-Nield LD, Radcliffe RA, Malkinson AM, and Agarwal R (2009) Growth inhibition and regression of lung tumors by silibinin: Modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res (Phila) 2:74-83.
53. Verschueren K, Remacle JE, Collart C, Kraft H, Baker BS, Tylzanowski P, Nelles L, Wuytens G, Su MT, and Bodmer R, et al. (1999) SIP1, a novel zinc finger/ homeodomain repressor, interacts with Smad proteins and binds to 59-CACCT sequences in candidate target genes. J Biol Chem 274:20489-20498.
54. Witta SE, Dziadziuszko R, Yoshida K, Hedman K, Varella-Garcia M, Bunn PA, Jr, and Hirsch FR (2009) ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Ann Oncol 20:689-695.
55. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, and Sugita M, et al. (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66:944-950. (Pubitemid 43165962)
56. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, and Seshagiri S, et al. (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11:8686-8698. (Pubitemid 43005918)
57. Zavadil J, Haley J, Kalluri R, Muthuswamy SK, and Thompson E (2008) Epithelialmesenchymal transition. Cancer Res 68:9574-9577.
58. Zhang W, Peyton M, Xie Y, Soh J, Minna JD, Gazdar AF, and Frenkel EP (2009) Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. J Thorac Oncol 4:161-166.
59. Zhong S, Fields CR, Su N, Pan YX, and Robertson KD (2007) Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 26:2621-2634. (Pubitemid 46632003)
60. Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, and Minna JD (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61:249-255. (Pubitemid 32095725)